Brentuximab vedotin elicited a response in 86% of the 58 ALCL patients. We don't know how long the median response rate was because many of the patients are still responding, but it appears it'll be longer than six months because that's where the median follow-up currently stands. That's not bad for patients who failed earlier treatment or couldn't take the medication in the first place.
So if the results were so great and the first trial sent shares up more than 17%, how come shares barely budged yesterday, up just 0.2%? Expectations, my dear Fool, expectations.
Remember the first results came after Seattle Genetics' lintuzumab failed its clinical trial in acute myeloid leukemia. All hopes lay on brentuximab vedotin before the first trial was released, but a positive result on the second trial was somewhat expected.
The first trial was also a confirmation that the company's antibody-drug conjugate technology works. Since Seattle Genetics has licensed the technology to numerous companies -- Bayer, Celldex Therapeutics
Most importantly, the difference in going from zero to one approved drug is a lot bigger than going from one indication to two. Once the drug is on the market, a drugmaker is only allowed to market it for the approved indication, but doctors can generally prescribe it for anything they want. So-called off-label prescriptions can result in substantial sales, especially in the time between when a drug is shown to work in a clinical trial and when it's approved for the indication.
An approval -- any approval -- is important because Seattle Genetics will almost certainly go after patients earlier in their disease progression. Having brentuximab vedotin already on the market will help it go up directly against drugs such as Roche and Biogen Idec's
Think of it as a how-not-to-do-it guide: Dan Dzombak breaks down the top five ways to lose money investing.
GlaxoSmithKline is a Motley Fool Global Gains recommendation. Investing internationally doesn't have to be scary and it can certainly be profitable. Click here to grab a 30-day trial subscription to the newsletter where you'll see all of our current picks for a global economy.
True to its name, The Motley Fool is made up of a motley assortment of writers and analysts, each with a unique perspective; sometimes we agree, sometimes we disagree, but we all believe in the power of learning from each other through our Foolish community.
More from The Motley Fool
5 Biotech Buyout Candidates for 2018
The Republican-inspired U.S. tax reform could spur an acquisition bonanza in biotech next year. Here's a look at five companies that might be prime targets.
Why Seattle Genetics, Inc. Fell Today
Investors aren't particularly excited about data presented at the American Society of Hematology meeting.
3 High-Yield Dividend Stocks to Buy in 2018
These 3 Big Pharma stocks may be worth adding to your portfolio in 2018.